Collaboration Seeks to Reduce Prostate Cancer Disparities in African Americans

Collaboration Seeks to Reduce Prostate Cancer Disparities in African Americans
The Prostate Cancer Foundation (PCF) and Robert F. Smith, chairman and CEO of Vista Equity Partners are supporting research on a new non-invasive genetic test to determine a man's risk of developing prostate cancer. Named the Smith Polygenic Risk Test for Prostate Cancer, the tool is part of PCF’s large initiative to reduce prostate cancer disparities in African American men, who are 76% more likely to develop prostate cancer than Caucasians, and twice as likely to die from it compared to other races. The research, led by Chris Haiman, a genetic epidemiologist at the University of Southern California, aims to improve early detection of this disease and reduce the disparities of prostate cancer in African American men by 2030. “As African American men are at an increased risk for being diagnosed or dying from prostate cancer, understanding their risk profile and applying this knowledge earlier with strategic detection, care, and decisions about cancer risk management is of utmost importance to address health inequity in the U.S.,” Smith said in a press release. “This is why I made a personal commitment to help accelerate research, encourage African American men to participate in the study and subsequent testing, and develop new detection strategies that have the power to transform how we diagnose and treat this disease and help save lives,” he said. The Smith Polygenic Risk Test for Prostate Cancer is a non-invasive test designed to determine a man's risk of developing prostate cancer. It analyzes more than 250 genetic variants linked to the disease using a single sample of saliva or blood. The test, which is expected to cost less than $90, will be available in PCF’s dedicated Veterans Affairs (VA) network of Centers of Excellence, including
Subscribe or to access all post and page content.